Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 66
Filtrar
1.
J Am Acad Orthop Surg ; 27(8): e390-e394, 2019 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-30216246

RESUMO

INTRODUCTION: Postoperative C5 nerve root palsy is a known complication after cervical surgery. The effect of increasing number of levels fused on the prevalence of C5 palsy after anterior cervical diskectomy and fusion (ACDF) is unclear. METHODS: Medical records of ACDF patients that included the C4-5 level at one institution were retrospectively reviewed. C5 palsy was defined as motor decline of the deltoid and/or biceps brachii muscle function by at least 1 level on standard manual muscle testing. RESULTS: A total of 196 patients met the inclusion criteria, with no significant differences noted between groups undergoing single- or multi-level ACDF. The overall C5 palsy rate was 5.1%. Palsy rates were not statistically significant based on the number of levels fused. Six of the 10 patients with C5 palsy had complete recovery of motor strength, whereas 2 patients had at least some level of strength recovery. CONCLUSION: The overall C5 palsy rate was 5.1% for all patients undergoing up to four-level ACDF. The rate of postoperative motor decline was lowest in the patients undergoing two-level ACDF and highest in the single-level group, but this finding did not reach statistical significance. The prognosis for strength recovery by final follow-up is excellent. LEVEL OF EVIDENCE: Level III, Case-control.


Assuntos
Vértebras Cervicais/cirurgia , Discotomia , Paralisia/enzimologia , Complicações Pós-Operatórias/epidemiologia , Fusão Vertebral , Estudos de Casos e Controles , Feminino , Seguimentos , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
2.
Glia ; 66(9): 1960-1971, 2018 09.
Artigo em Inglês | MEDLINE | ID: mdl-29726608

RESUMO

Myelinating glial cells (MGCs), oligodendrocytes (OLs) in the central nervous system (CNS) and Schwann cells (SCs) in the peripheral nervous system (PNS), generate myelin sheaths that insulate axons. After myelination is completed in adulthood, MGC functions independent from myelin are required to support axon survival, but the underlying mechanisms are still unclear. Dicer is a key enzyme that is responsible for generating functional micro-RNAs (miRNAs). Despite the importance of Dicer in initiating myelination, the role of Dicer in mature MGCs is still unclear. Here, Dicer was specifically deleted in mature MGCs in 2-month old mice (PLP-CreERT; Dicer fl/fl) by tamoxifen administration. Progressive motor dysfunction was observed in the Dicer conditional knockout mice, which displayed hind limb ataxia at 3 months post recombination that deteriorated into paralysis within 5 months. Massive axonal degeneration/atrophy in peripheral nerves was responsible for this phenomenon, but overt demyelination was not observed in either the CNS or PNS. In contrast to the PNS, signs of axonal degeneration were not observed in the CNS of these animals. We induced a Dicer deletion in oligodendroglia at postnatal day 5 in NG2-CreERT; Dicer fl/fl mice to evaluate whether Dicer expression in OLs is essential for axonal survival. Dicer deletion in oligodendroglia did not cause motor dysfunction at the age of 7 months. Neither axonal atrophy nor demyelination was observed in the CNS. Based on our results, Dicer expression in SCs is required to maintain axon integrity in adult PNS, and Dicer is dispensable for maintaining myelin sheaths in MGCs.


Assuntos
Axônios/enzimologia , RNA Helicases DEAD-box/deficiência , Bainha de Mielina/enzimologia , Degeneração Neural/enzimologia , Ribonuclease III/deficiência , Animais , Ataxia/enzimologia , Ataxia/patologia , Atrofia , Axônios/patologia , RNA Helicases DEAD-box/genética , Progressão da Doença , Feminino , Masculino , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Atividade Motora/fisiologia , Bainha de Mielina/patologia , Degeneração Neural/patologia , Nervo Óptico/enzimologia , Nervo Óptico/patologia , Paralisia/enzimologia , Paralisia/patologia , Ribonuclease III/genética , Nervo Isquiático/enzimologia , Nervo Isquiático/patologia , Medula Espinal/enzimologia , Medula Espinal/patologia , Substância Branca/enzimologia , Substância Branca/patologia
3.
Pestic Biochem Physiol ; 143: 1-7, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-29183576

RESUMO

Popillia japonica is a generalist herbivore that feeds on >300 host plant species in at least 72 plant families. It is unknown why P. japonica, despite possessing active detoxification enzymes in its gut, is paralyzed when feeding on the petals of one of its preferred host plant, Pelargonium×hortorum, or on artificial diet containing quisqualic acid (QA), the active compound in zonal geranium. We hypothesized that Pelargonium×hortorum or QA do not induce activity of the cytochrome P450, glutathione S transferase (GST), and carboxylesterase (CoE) detoxification enzymes in P. japonica. In this study, P. japonica were fed petals of zonal geranium or agar plugs containing QA, or rose petals, another preferred but non-toxic host. Midgut enzyme activities of P450, GST, and CoE were then assayed after 6, 12, or 24h of feeding. In most cases, P450, GST, and CoE activities were significantly induced in P. japonica midguts by geranium petals and QA, though the induction was slower than with rose petals. Induced enzyme activity reached a peak at 24h after consumption, which coincides with the period of highest recovery from geranium and QA paralysis. This study shows that toxic geranium and QA induce detoxification enzyme activity, but the induced enzymes do not effectively protect P. japonica from paralysis by QA. Further investigation is required through in vitro studies to know if the enzymes induced by geranium are capable of metabolizing QA. This study highlights a rare physiological mismatch between the detoxification tool kit of a generalist and its preferred host.


Assuntos
Besouros/efeitos dos fármacos , Geranium/toxicidade , Ácido Quisquálico/toxicidade , Animais , Carboxilesterase/metabolismo , Besouros/enzimologia , Sistema Enzimático do Citocromo P-450/metabolismo , Citosol/efeitos dos fármacos , Citosol/enzimologia , Indução Enzimática/efeitos dos fármacos , Flores/toxicidade , Glutationa Transferase/metabolismo , Inativação Metabólica , Intestinos/efeitos dos fármacos , Intestinos/enzimologia , Microssomos/efeitos dos fármacos , Microssomos/enzimologia , Paralisia/induzido quimicamente , Paralisia/enzimologia , Rosa/toxicidade
4.
Microb Pathog ; 111: 395-401, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28916318

RESUMO

Inflammation in Guillain-Barré syndrome (GBS) is manifested by changes in matrix metalloproteinase (MMP) and pro-inflammatory cytokine expression. We investigated the expression of MMP-2, -9 and TNF-α and correlated it with pathological changes in sciatic nerve tissue from Campylobacter jejuni-induced chicken model for GBS. Campylobacter jejuni and placebo were fed to chickens and assessed for disease symptoms. Sciatic nerves were examined by histopathology and immunohistochemistry. Expressions of MMPs and TNF-α, were determined by real-time PCR, and activities of MMPs by zymography. Diarrhea developed in 73.3% chickens after infection and 60.0% of them developed GBS like neuropathy. Pathology in sciatic nerves showed perinodal and/or patchy demyelination, perivascular focal lymphocytic infiltration and myelin swelling on 10th- 20th post infection day (PID). MMP-2, -9 and TNF-α were up-regulated in progressive phase of the disease. Enhanced MMP-2, -9 and TNF-α production in progressive phase correlated with sciatic nerve pathology in C. jejuni-induced GBS chicken model.


Assuntos
Infecções por Campylobacter/enzimologia , Campylobacter jejuni/fisiologia , Síndrome de Guillain-Barré/enzimologia , Metaloproteinase 2 da Matriz/metabolismo , Metaloproteinase 9 da Matriz/metabolismo , Paralisia/enzimologia , Animais , Infecções por Campylobacter/genética , Infecções por Campylobacter/microbiologia , Infecções por Campylobacter/patologia , Campylobacter jejuni/genética , Galinhas , Modelos Animais de Doenças , Síndrome de Guillain-Barré/genética , Síndrome de Guillain-Barré/microbiologia , Síndrome de Guillain-Barré/patologia , Humanos , Metaloproteinase 2 da Matriz/genética , Metaloproteinase 9 da Matriz/genética , Paralisia/genética , Paralisia/microbiologia , Nervo Isquiático/enzimologia , Nervo Isquiático/microbiologia , Nervo Isquiático/patologia , Fator de Necrose Tumoral alfa/genética , Fator de Necrose Tumoral alfa/metabolismo
5.
J Biol Chem ; 290(47): 28097-28106, 2015 Nov 20.
Artigo em Inglês | MEDLINE | ID: mdl-26400084

RESUMO

Glutathione peroxidase 4 (GPX4), an antioxidant defense enzyme active in repairing oxidative damage to lipids, is a key inhibitor of ferroptosis, a non-apoptotic form of cell death involving lipid reactive oxygen species. Here we show that GPX4 is essential for motor neuron health and survival in vivo. Conditional ablation of Gpx4 in neurons of adult mice resulted in rapid onset and progression of paralysis and death. Pathological inspection revealed that the paralyzed mice had a dramatic degeneration of motor neurons in the spinal cord but had no overt neuron degeneration in the cerebral cortex. Consistent with the role of GPX4 as a ferroptosis inhibitor, spinal motor neuron degeneration induced by Gpx4 ablation exhibited features of ferroptosis, including no caspase-3 activation, no TUNEL staining, activation of ERKs, and elevated spinal inflammation. Supplementation with vitamin E, another inhibitor of ferroptosis, delayed the onset of paralysis and death induced by Gpx4 ablation. Also, lipid peroxidation and mitochondrial dysfunction appeared to be involved in ferroptosis of motor neurons induced by Gpx4 ablation. Taken together, the dramatic motor neuron degeneration and paralysis induced by Gpx4 ablation suggest that ferroptosis inhibition by GPX4 is essential for motor neuron health and survival in vivo.


Assuntos
Morte Celular , Glutationa Peroxidase/genética , Neurônios Motores/patologia , Paralisia/enzimologia , Animais , Glutationa Peroxidase/metabolismo , Camundongos , Camundongos Knockout , Neurônios Motores/metabolismo , Fosfolipídeo Hidroperóxido Glutationa Peroxidase , Espécies Reativas de Oxigênio/metabolismo , Medula Espinal/metabolismo , Medula Espinal/patologia
6.
CNS Neurol Disord Drug Targets ; 13(4): 691-8, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24576002

RESUMO

Alzheimer's disease (AD) represents a neurological disorder, which is caused by enzymatic degradation of an amyloid precursor protein into short peptide fragments that undergo association to form insoluble plaques. Preliminary studies suggest that cyanobacterial extracts, especially the light-harvesting protein phycocyanin, may provide a means to control the progression of the disease. However, the molecular mechanism of disease control remains elusive. In the present study, intact hexameric phycocyanin was isolated and crystallized from the cyanobacterium Leptolyngbya sp. N62DM, and the structure was solved to a resolution of 2.6 A. Molecular docking studies show that the phycocyanin αß-dimer interacts with the enzyme ß-secretase, which catalyzes the proteolysis of the amyloid precursor protein to form plaques. The molecular docking studies suggest that the interaction between phycocyanin and ß-secretase is energetically more favorable than previously reported inhibitor-ß-secretase interactions. Transgenic Caenorhabditis elegans worms, with a genotype to serve as an AD-model, were significantly protected by phycocyanin. Therefore, the present study provides a novel structure-based molecular mechanism of phycocyanin-mediated therapy against AD.


Assuntos
Secretases da Proteína Precursora do Amiloide/química , Proteínas de Bactérias/química , Fármacos Neuroprotetores/química , Ficocianina/química , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/enzimologia , Animais , Animais Geneticamente Modificados , Proteínas de Bactérias/isolamento & purificação , Proteínas de Bactérias/farmacologia , Caenorhabditis elegans , Cianobactérias , Modelos Animais de Doenças , Simulação de Acoplamento Molecular , Fármacos Neuroprotetores/isolamento & purificação , Fármacos Neuroprotetores/farmacologia , Paralisia/tratamento farmacológico , Paralisia/enzimologia , Ficocianina/isolamento & purificação , Ficocianina/farmacologia , Conformação Proteica , Difração de Raios X
7.
J Cell Sci ; 126(Pt 14): 3151-8, 2013 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-23641070

RESUMO

Triosephosphate isomerase (TPI) is a glycolytic enzyme that converts dihydroxyacetone phosphate (DHAP) into glyceraldehyde 3-phosphate (GAP). Glycolytic enzyme dysfunction leads to metabolic diseases collectively known as glycolytic enzymopathies. Of these enzymopathies, TPI deficiency is unique in the severity of neurological symptoms. The Drosophila sugarkill mutant closely models TPI deficiency and encodes a protein prematurely degraded by the proteasome. This led us to question whether enzyme catalytic activity was crucial to the pathogenesis of TPI sugarkill neurological phenotypes. To study TPI deficiency in vivo we developed a genomic engineering system for the TPI locus that enables the efficient generation of novel TPI genetic variants. Using this system we demonstrate that TPI sugarkill can be genetically complemented by TPI encoding a catalytically inactive enzyme. Furthermore, our results demonstrate a non-metabolic function for TPI, the loss of which contributes significantly to the neurological dysfunction in this animal model.


Assuntos
Anemia Hemolítica Congênita não Esferocítica/enzimologia , Erros Inatos do Metabolismo dos Carboidratos/enzimologia , Drosophila melanogaster/fisiologia , Longevidade , Paralisia/enzimologia , Triose-Fosfato Isomerase/deficiência , Triose-Fosfato Isomerase/metabolismo , Anemia Hemolítica Congênita não Esferocítica/genética , Animais , Erros Inatos do Metabolismo dos Carboidratos/genética , Catálise , Fosfato de Di-Hidroxiacetona/metabolismo , Modelos Animais de Doenças , Drosophila melanogaster/enzimologia , Feminino , Técnicas de Inativação de Genes , Teste de Complementação Genética , Engenharia Genética , Gliceraldeído 3-Fosfato/metabolismo , Glicólise/genética , Temperatura Alta/efeitos adversos , Masculino , Mutação/genética , Paralisia/genética , Estresse Fisiológico/genética , Transgenes/genética , Triose-Fosfato Isomerase/genética
8.
Neurosci Res ; 71(3): 266-77, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21824499

RESUMO

c-Jun N-terminal kinase (JNK) mediates neuronal death in response to stress and injury in the CNS and peripheral nervous system. Here, we show that JNK also regulates retrograde axonal degeneration (axonal dieback) after spinal cord injury (SCI) in mice. Activated phospho-JNK was highly expressed in damaged corticospinal tract (CST) axons after thoracic SCI by hemisection. Local administration of SP600125, a JNK inhibitor, prevented accumulation of amyloid-ß precursor protein and retraction of the severed CST axons as well as preserved the axonal arbors rostral to the injury site. The treatment with SP600125 also improved functional recovery of the hindlimbs, assessed by Basso mouse scale open-field scores and the grid-walking test. In Jnk1(-/-) and Jnk3(-/-) mice, we observed prevention of axonal degeneration and enhancement of motor recovery after SCI. These results indicate that both JNK1 and JNK3 induce axonal degeneration and limit motor recovery after SCI. Thus, a JNK inhibitor may be a suitable therapeutic agent for SCI.


Assuntos
Proteína Quinase 10 Ativada por Mitógeno/genética , Proteína Quinase 8 Ativada por Mitógeno/fisiologia , Recuperação de Função Fisiológica , Traumatismos da Medula Espinal/enzimologia , Animais , Antracenos/administração & dosagem , Modelos Animais de Doenças , Feminino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Proteína Quinase 10 Ativada por Mitógeno/antagonistas & inibidores , Proteína Quinase 10 Ativada por Mitógeno/deficiência , Proteína Quinase 8 Ativada por Mitógeno/antagonistas & inibidores , Proteína Quinase 8 Ativada por Mitógeno/deficiência , Regeneração Nervosa/efeitos dos fármacos , Regeneração Nervosa/genética , Paralisia/enzimologia , Paralisia/genética , Paralisia/fisiopatologia , Recuperação de Função Fisiológica/efeitos dos fármacos , Recuperação de Função Fisiológica/genética , Traumatismos da Medula Espinal/patologia , Traumatismos da Medula Espinal/fisiopatologia , Degeneração Walleriana/enzimologia , Degeneração Walleriana/patologia , Degeneração Walleriana/fisiopatologia
9.
Dis Model Mech ; 4(2): 193-202, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21135058

RESUMO

Axon degeneration is observed in neurodegenerative diseases and neuroinflammatory disorders, such as Alzheimer's disease, Parkinson's disease and multiple sclerosis. The molecular basis of this process remains largely unknown. Here, we show that mice deleted for the tumour suppressor LKB1 (also called STK11) in the spinal cord, some parts of the brain and in the endocrine pancreas (ßLKB1KO mice) develop hind-limb dysfunction and axon degeneration at about 7 weeks. Demyelination and macrophage infiltration are observed in the white matter of these mice, predominantly in the bilateral and anterior funiculi of the thoracic segment of the spinal cord, suggesting damage to the ascending sensory signalling pathway owing to LKB1 deletion in the brain. Microtubule structures were also affected in the degenerated foci, with diminished neurofilament and tubulin expression. Deletion of both PRKAA1 genes, whose products AMPKα1 and AMPKα2 are also downstream targets of LKB1, with the same strategy was without effect. We thus define LKB1 as an intrinsic suppressor of axon degeneration and a possible target for strategies that can reverse this process.


Assuntos
Axônios/patologia , Membro Posterior/patologia , Degeneração Neural/complicações , Paralisia/complicações , Proteínas Serina-Treonina Quinases/metabolismo , Proteína Serina-Treonina Quinase 2 de Interação com Receptor/metabolismo , Medula Espinal/patologia , Proteínas Quinases Ativadas por AMP/metabolismo , Animais , Domínio Catalítico , Movimento Celular , Deleção de Genes , Membro Posterior/fisiopatologia , Integrases/metabolismo , Macrófagos/patologia , Camundongos , Camundongos Knockout , Microtúbulos/patologia , Atividade Motora , Degeneração Neural/fisiopatologia , Paralisia/enzimologia , Paralisia/fisiopatologia , Proteínas Serina-Treonina Quinases/deficiência , Células Receptoras Sensoriais/metabolismo , Células Receptoras Sensoriais/patologia , Transdução de Sinais , Medula Espinal/enzimologia , Medula Espinal/fisiopatologia , Transgenes/genética
10.
J Toxicol Sci ; 35(6): 795-805, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21139329

RESUMO

Botulinum neurotoxin serotype A (BoNT/A) inhibits acetylcholine release at the neuromuscular junction in isolated muscles, and ouabain can partially block its effect. However, it is not clear whether ouabain attenuates BoNT/A-induced neuromuscular paralysis in vivo. In this work, we investigated the effects of ouabain on BoNT/A-induced neuromuscular paralysis in mice. Ouabain was administered to mice intraperitoneally immediately after a single injection of BoNT/A into skeletal muscle. The effects of ouabain on BoNT/A-induced muscle paralysis were assessed by quantitative monitoring of muscle tension and digit abduction via the digit abduction scoring (DAS) assay. A single administration of ouabain significantly prolonged BoNT/A-induced neuromuscular paralysis. Moreover, consecutive daily injection of ouabain exacerbated BoNT/A-induced neuromuscular paralysis, and led to a significant decrease in both twitch and tetanic forces as assayed in isolated BoNT/A-injected muscles. We next looked at the effects of ouabain on BoNT/A-induced muscle atrophy. Administration of ouabain led to a decrease in the myofibrillar cross-sectional area (CSAs) by 14 post-BoNT/A injection. In addition, repeated administration of ouabain increased mRNA expression levels of ubiquitin ligases, which are markers of muscle atrophy, in BoNT/A-injected muscle. These results suggest that ouabain exacerbates BoNT/A-induced neuromuscular paralysis via a marked progression of BoNT/A-induced muscle atrophy.


Assuntos
Toxinas Botulínicas Tipo A/toxicidade , Músculo Esquelético/efeitos dos fármacos , Atrofia Muscular/induzido quimicamente , Ouabaína/toxicidade , Paralisia/induzido quimicamente , Animais , Sinergismo Farmacológico , Injeções Intramusculares , Injeções Intraperitoneais , Masculino , Camundongos , Camundongos Endogâmicos , Proteínas Musculares/biossíntese , Músculo Esquelético/enzimologia , Atrofia Muscular/complicações , Atrofia Muscular/enzimologia , Paralisia/complicações , Paralisia/enzimologia , RNA/biossíntese , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Proteínas com Motivo Tripartido , Ubiquitina-Proteína Ligases/biossíntese
11.
Hum Mol Genet ; 19(24): 4774-89, 2010 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-20871097

RESUMO

Mutations in superoxide dismutase 1 (SOD1) are associated with familial cases of amyotrophic lateral sclerosis (fALS). Studies in transgenic mice have suggested that wild-type (WT) SOD1 can modulate the toxicity of mutant SOD1. In the present study, we demonstrate that the effects of WT SOD1 on the age at which transgenic mice expressing mutant human SOD1 (hSOD1) develop paralysis are influenced by the nature of the ALS mutation and the expression levels of WT hSOD1. We show that regardless of whether WT SOD1 changes the course of disease, both WT and mutant hSOD1 accumulate as detergent-insoluble aggregates in symptomatic mice expressing both proteins. However, using a panel of fluorescently tagged variants of SOD1 in a cell model of mutant SOD1 aggregation, we demonstrate that the interactions between mutant and WT SOD1 in aggregate formation are not simply a co-assembly of mutant and WT proteins. Overall, these data demonstrate that the product of the normal SOD1 allele in fALS has potential to influence the toxicity of mutant SOD1 and that complex interactions with the mutant protein may influence the formation of aggregates and inclusion bodies generated by mutant SOD1.


Assuntos
Esclerose Lateral Amiotrófica/enzimologia , Esclerose Lateral Amiotrófica/patologia , Proteínas Mutantes/química , Proteínas Mutantes/metabolismo , Superóxido Dismutase/metabolismo , Envelhecimento/efeitos dos fármacos , Esclerose Lateral Amiotrófica/complicações , Animais , Células Cultivadas , Detergentes/farmacologia , Corpos de Inclusão/efeitos dos fármacos , Corpos de Inclusão/metabolismo , Camundongos , Camundongos Transgênicos , Modelos Biológicos , Proteínas Mutantes/genética , Paralisia/complicações , Paralisia/enzimologia , Paralisia/patologia , Ligação Proteica/efeitos dos fármacos , Estrutura Quaternária de Proteína , Solubilidade/efeitos dos fármacos , Medula Espinal/efeitos dos fármacos , Medula Espinal/enzimologia , Medula Espinal/patologia , Superóxido Dismutase/genética , Superóxido Dismutase-1
12.
Proc Natl Acad Sci U S A ; 107(4): 1636-41, 2010 Jan 26.
Artigo em Inglês | MEDLINE | ID: mdl-20080621

RESUMO

The enzyme ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is one of the most abundant proteins in the mammalian nervous system. In humans, UCH-L1 is also found in the ubiquitinated inclusion bodies that characterize neurodegenerative diseases in the brain, suggesting its involvement in neurodegeneration. The physiologic role of UCH-L1 in neurons, however, remains to be further elucidated. For example, previous studies have provided evidence both for and against the role of UCH-L1 in synaptic function in the brain. Here, we have characterized a line of knockout mice deficient in the UCH-L1 gene. We found that, in the absence of UCH-L1, synaptic transmission at the neuromuscular junctions (NMJs) is markedly impaired. Both spontaneous and evoked synaptic activity are reduced; paired pulse-facilitation is impaired, and synaptic transmission fails to respond to high-frequency, repetitive stimulation at the NMJs of UCH-L1 knockout mice. Morphologic analyses of the NMJs further revealed profound structural defects-loss of synaptic vesicles and accumulation of tubulovesicular structures at the presynaptic nerve terminals, and denervation of the muscles in UCH-L1 knockout mice. These findings demonstrate that UCH-L1 is required for the maintenance of the structure and function of the NMJ and that the loss of normal UCH-L1 activity may result in neurodegeneration in the peripheral nervous system.


Assuntos
Junção Neuromuscular/citologia , Junção Neuromuscular/enzimologia , Ubiquitina Tiolesterase/metabolismo , Animais , Progressão da Doença , Camundongos , Camundongos Knockout , Microscopia Eletrônica de Transmissão , Mutação , Paralisia/enzimologia , Paralisia/genética , Paralisia/patologia , Transmissão Sináptica , Ubiquitina Tiolesterase/deficiência , Ubiquitina Tiolesterase/genética
13.
Neurol Res ; 30(7): 761-7, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18593519

RESUMO

OBJECTIVE: The complement system and activated neutrophils are thought to play a major role in initiating some of the inflammatory events that occur in spinal cord injury. The aim of the present study was to assess the effects of C1 esterase inhibitor (C1-INH) on traumatic spinal cord injury (SCI) in the rat. METHODS: Thirty-eight male Wistar rats were used. Just after SCI by a pneumatic impact device, C1-INH (n=16, C1-INH group) or saline (n=16, saline group) was administered. Sham operated animals (n=6, sham group) received only laminectomy. Eighteen (six from each group) rats were killed and an assessment of leukocyte infiltration by myeloperoxidase (MPO) activity and immunoreactivity of MPO were performed 24 hours after SCI. Twenty (ten from each of C1-INH and saline groups) rats were examined using behavioral function on post-operative days. They were also examined after 7 days by histologic analysis using Luxol fast blue for axons and myelin. Lesion volume was calculated by considering a lesion as being composed of two cones with juxtaposed bases. During the experiment, sequential changes in regional spinal cord blood flow (rSCBF) were measured using the laser Doppler (LD) scanning technique. RESULTS: The recovery of motor function was better in the C1-INH group than in the saline group. In the C1-INH group, immunoreactivity of MPO showed a tendency to be smaller than that of the saline group. Lesion volume was significantly smaller in the C1-INH group than in the control group (p<0.01) and MPO activity was also significantly smaller in the C1-INH group than in the control group (p<0.01). After SCI, the rSCBF value decreased gradually and significantly in both injured groups. Significant differences were observed from 30 to 120 minutes after SCI (p<0.05). DISCUSSION: The results of this study provided the first evidence that C1-INH reduced accumulation of polymorphonuclear leukocytes (PMLs) and neuronal damage in acute stage after SCI. This protection was not related to an improvement in rSCBF.


Assuntos
Proteína Inibidora do Complemento C1/farmacologia , Complemento C1s/antagonistas & inibidores , Fármacos Neuroprotetores/farmacologia , Traumatismos da Medula Espinal/tratamento farmacológico , Traumatismos da Medula Espinal/enzimologia , Medula Espinal/efeitos dos fármacos , Animais , Quimiotaxia de Leucócito/efeitos dos fármacos , Quimiotaxia de Leucócito/imunologia , Proteína Inibidora do Complemento C1/uso terapêutico , Complemento C1s/metabolismo , Proteínas do Sistema Complemento/imunologia , Proteínas do Sistema Complemento/metabolismo , Modelos Animais de Doenças , Imuno-Histoquímica , Masculino , Degeneração Neural/tratamento farmacológico , Degeneração Neural/enzimologia , Degeneração Neural/fisiopatologia , Fármacos Neuroprotetores/uso terapêutico , Neutrófilos/efeitos dos fármacos , Neutrófilos/enzimologia , Paralisia/tratamento farmacológico , Paralisia/enzimologia , Paralisia/fisiopatologia , Peroxidase/análise , Peroxidase/imunologia , Peroxidase/metabolismo , Ratos , Ratos Wistar , Recuperação de Função Fisiológica/efeitos dos fármacos , Recuperação de Função Fisiológica/fisiologia , Fluxo Sanguíneo Regional/efeitos dos fármacos , Fluxo Sanguíneo Regional/fisiologia , Medula Espinal/irrigação sanguínea , Medula Espinal/fisiopatologia , Traumatismos da Medula Espinal/fisiopatologia , Resultado do Tratamento
14.
J Biol Chem ; 283(27): 18883-91, 2008 Jul 04.
Artigo em Inglês | MEDLINE | ID: mdl-18434312

RESUMO

The seven antigenically distinct serotypes of Clostridium botulinum neurotoxins cleave specific soluble N-ethylmaleimide-sensitive factor attachment protein receptor complex proteins and block the release of neurotransmitters that cause flaccid paralysis and are considered potential bioweapons. Botulinum neurotoxin type A is the most potent among the clostridial neurotoxins, and to date there is no post-exposure therapeutic intervention available. To develop inhibitors leading to drug design, it is imperative that critical interactions between the enzyme and the substrate near the active site are known. Although enzyme-substrate interactions at exosites away from the active site are mapped in detail for botulinum neurotoxin type A, information about the active site interactions is lacking. Here, we present the crystal structures of botulinum neurotoxin type A catalytic domain in complex with four inhibitory substrate analog tetrapeptides, viz. RRGC, RRGL, RRGI, and RRGM at resolutions of 1.6-1.8 A. These structures show for the first time the interactions between the substrate and enzyme at the active site and delineate residues important for substrate stabilization and catalytic activity. We show that OH of Tyr(366) and NH(2) of Arg(363) are hydrogen-bonded to carbonyl oxygens of P1 and P1' of the substrate analog and position it for catalytic activity. Most importantly, the nucleophilic water is replaced by the amino group of the N-terminal residue of the tetrapeptide. Furthermore, the S1' site is formed by Phe(194), Thr(215), Thr(220), Asp(370), and Arg(363). The K(i) of the best inhibitory tetrapeptide is 157 nm.


Assuntos
Armas Biológicas , Toxinas Botulínicas Tipo A/antagonistas & inibidores , Toxinas Botulínicas Tipo A/química , Clostridium botulinum/enzimologia , Inibidores Enzimáticos/química , Oligopeptídeos/química , Sítios de Ligação , Toxinas Botulínicas Tipo A/toxicidade , Cristalografia por Raios X , Inibidores Enzimáticos/uso terapêutico , Oligopeptídeos/uso terapêutico , Paralisia/induzido quimicamente , Paralisia/tratamento farmacológico , Paralisia/enzimologia , Estrutura Terciária de Proteína/fisiologia , Relação Estrutura-Atividade
15.
J Biol Chem ; 283(9): 5908-17, 2008 Feb 29.
Artigo em Inglês | MEDLINE | ID: mdl-18086666

RESUMO

Neuropathy target esterase (NTE) is a member of the family of patatin domain-containing proteins and exhibits phospholipase activity in brain and cultured cells. NTE was originally identified as target enzyme for organophosphorus compounds that cause a delayed paralyzing syndrome with degeneration of nerve axons. Here we show that the structurally related murine protein NTE-related esterase (NRE) is a potent lysophospholipase. The enzyme efficiently hydrolyzes sn-1 esters in lysophosphatidylcholine and lysophosphatidic acid. No lipase activity was observed when triacylglycerols, cholesteryl esters, retinyl esters, phosphatidylcholine, or monoacylglycerol were used as substrates. Although NTE is predominantly expressed in the nervous system, we found the highest NRE mRNA levels in testes, skeletal muscle, cardiac muscle, and adipose tissue. Induction of NRE mRNA concentrations in these tissues during fasting suggested a nutritional regulation of enzyme expression and, in accordance with this observation, insulin reduced NRE mRNA levels in a dose-dependent manner in 3T3-L1 adipocytes. A green fluorescent protein-NRE fusion protein colocalized to the endoplasmic reticulum and lipid droplets. Thus, NRE is a previously unrecognized ER- and lipid droplet-associated lysophospholipase. Regulation of enzyme expression by the nutritional status and insulin suggests a role of NRE in the catabolism of lipid precursors and/or mediators that affect energy metabolism in mammals.


Assuntos
Hidrolases de Éster Carboxílico/metabolismo , Regulação Enzimológica da Expressão Gênica/fisiologia , Hipoglicemiantes/farmacologia , Insulina/farmacologia , Metabolismo dos Lipídeos/fisiologia , Lisofosfolipase/biossíntese , Células 3T3-L1 , Animais , Axônios/enzimologia , Encéfalo/enzimologia , Hidrolases de Éster Carboxílico/genética , Relação Dose-Resposta a Droga , Retículo Endoplasmático/enzimologia , Retículo Endoplasmático/genética , Jejum/fisiologia , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Metabolismo dos Lipídeos/efeitos dos fármacos , Lisofosfatidilcolinas/genética , Lisofosfatidilcolinas/metabolismo , Lisofosfolipase/genética , Lisofosfolipídeos/genética , Lisofosfolipídeos/metabolismo , Masculino , Camundongos , Especificidade de Órgãos/fisiologia , Paralisia/enzimologia , Paralisia/genética , RNA Mensageiro/biossíntese , RNA Mensageiro/genética , Especificidade por Substrato/fisiologia , Síndrome
16.
Proc Natl Acad Sci U S A ; 103(41): 14987-93, 2006 Oct 10.
Artigo em Inglês | MEDLINE | ID: mdl-17008404

RESUMO

To identify genes required for maintaining neuronal viability, we screened our collection of Drosophila temperature-sensitive paralytic mutants for those exhibiting shortened lifespan and neurodegeneration. Here, we describe the characterization of wasted away (wstd), a recessive, hypomorphic mutation that causes progressive motor impairment, vacuolar neuropathology, and severely reduced lifespan. We demonstrate that the affected gene encodes the glycolytic enzyme, triosephosphate isomerase (Tpi). Mutations causing Tpi deficiency in humans are also characterized by progressive neurological dysfunction, neurodegeneration, and early death. In Tpi-deficient flies and humans, a decrease in ATP levels did not appear to cause the observed phenotypes because ATP levels remained normal. We also found no genetic evidence that the mutant Drosophila Tpi was misfolded or involved in aberrant protein-protein associations. Instead, we favor the hypothesis that mutations in Tpi lead to an accumulation of methylglyoxal and the consequent enhanced production of advanced glycation end products, which are ultimately responsible for the death and dysfunction of Tpi-deficient neurons. Our results highlight an essential protective role of Tpi and support the idea that advanced glycation end products may also contribute to pathogenesis of other neurological disorders.


Assuntos
Proteínas de Drosophila/genética , Drosophila melanogaster/genética , Transtornos Heredodegenerativos do Sistema Nervoso/genética , Transtornos Heredodegenerativos do Sistema Nervoso/mortalidade , Mutagênese , Paralisia/genética , Paralisia/mortalidade , Triose-Fosfato Isomerase/genética , Animais , Modelos Animais de Doenças , Proteínas de Drosophila/deficiência , Drosophila melanogaster/enzimologia , Feminino , Produtos Finais de Glicação Avançada/biossíntese , Transtornos Heredodegenerativos do Sistema Nervoso/enzimologia , Transtornos Heredodegenerativos do Sistema Nervoso/patologia , Humanos , Masculino , Paralisia/enzimologia , Paralisia/patologia , Aldeído Pirúvico/metabolismo , Triose-Fosfato Isomerase/deficiência , Triose-Fosfato Isomerase/metabolismo
17.
Brain Res ; 1035(2): 206-10, 2005 Feb 28.
Artigo em Inglês | MEDLINE | ID: mdl-15722060

RESUMO

This study examined whether phenidone, a dual inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX), affects the clinical symptoms of experimental autoimmune encephalomyelitis (EAE) in the rat, and the expression of both COX-1/-2 and 5-LOX in EAE spinal cords. Oral phenidone (200 mg/kg) significantly suppressed the incidence and clinical severity of EAE paralysis. Western blot analysis showed that phenidone significantly inhibited the increases in COX-1/-2 and 5-LOX in the spinal cords of rats with EAE. This finding was paralleled by immunohistochemical observations. Overall, these findings suggest that COX-1/-2 and 5-LOX are important inflammatory mediators in the pathogenesis of EAE, and that the inhibition of both COX and LOX ameliorates the autoimmune disorder of the central nervous system.


Assuntos
Inibidores de Ciclo-Oxigenase/uso terapêutico , Encefalomielite Autoimune Experimental/tratamento farmacológico , Encefalomielite Autoimune Experimental/enzimologia , Inibidores de Lipoxigenase/uso terapêutico , Paralisia/tratamento farmacológico , Paralisia/enzimologia , Pirazóis/uso terapêutico , Animais , Araquidonato 5-Lipoxigenase/biossíntese , Ciclo-Oxigenase 1 , Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase 2 , Masculino , Proteínas de Membrana , Prostaglandina-Endoperóxido Sintases/biossíntese , Ratos , Ratos Endogâmicos Lew
18.
Neurotoxicology ; 24(1): 43-53, 2003 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-12564381

RESUMO

Muscle injury and its role in the development of Type II paralysis was studied in 25 patients with acute organophosphate poisoning. All patients were assessed for severity of poisoning at admission and through the course of poisoning for the development and duration of intermediate syndrome (IS) (Type II paralysis). Blood levels of acetylcholinesterase, creatine kinase, creatine kinase MM, LDH and LDH5 were estimated through the course of the poisoning. Of the 25 patients, 22 were severely poisoned and 3 had mild to moderate poisoning. Severely poisoned patients had a significantly greater rate of developing intermediate syndrome (17/22) (P = 0.026). Type I paralysis and fasciculations occurred in 76 and 70.5% of patients who developed intermediate syndrome, in comparison to 38 and 50%, respectively, of those who did not develop intermediate syndrome. Weakness developed in the same groups of muscles in both Types I and II paralysis but was of longer duration in patients who developed Type II paralysis. Acetylcholinesterase was inhibited > 90% throughout the course of poisoning with greater inhibition in patients with longer duration intermediate syndrome. Muscle injury was seen in all patients beginning at admission, peaking over the first 5 days and then declining over the next 5 days. Temporal profiles of blood muscle isoenzymes showed significantly greater muscle injury in those patients with greater severity of poisoning at admission, those who developed intermediate syndrome and in patients with longer duration intermediate syndrome. The findings of this study suggest that Types I and II paralysis in organophosphate poisoning are not separate syndromes but a clinical continuum determined by the severity of poisoning. The magnitude of organophosphate exposure and of muscle injury during the cholinergic crises appears to determine the occurrence and severity of intermediate syndrome.


Assuntos
Músculo Esquelético/efeitos dos fármacos , Intoxicação por Organofosfatos , Paralisia/induzido quimicamente , Acetilcolinesterase/metabolismo , Adulto , Humanos , Debilidade Muscular/induzido quimicamente , Debilidade Muscular/enzimologia , Debilidade Muscular/patologia , Músculo Esquelético/enzimologia , Músculo Esquelético/lesões , Músculo Esquelético/patologia , Paralisia/enzimologia , Paralisia/patologia , Estudos Prospectivos , Análise de Regressão , Estatísticas não Paramétricas
19.
J Virol ; 76(16): 8335-46, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12134038

RESUMO

We previously characterized the expression and function of the protein tyrosine phosphatase SHP-1 in the glia of the central nervous system (CNS). In the present study, we describe the role of SHP-1 in virus infection of glia and virus-induced demyelination in the CNS. For in vivo studies, SHP-1-deficient mice and their normal littermates received an intracerebral inoculation of an attenuated strain of Theiler's murine encephalomyelitis virus (TMEV). At various times after infection, virus replication, TMEV antigen expression, and demyelination were monitored. It was found that the CNS of SHP-1-deficient mice uniquely displayed demyelination and contained substantially higher levels of virus than did that of normal littermate mice. Many infected astrocytes and oligodendrocytes were detected in both brains and spinal cords of SHP-1-deficient but not normal littermate mice, showing that the virus replicated and spread at a much higher rate in the glia of SHP-1-deficient animals. To ascertain whether the lack of SHP-1 in the glia was primarily responsible for these differences, glial samples from these mice were cultured in vitro and infected with TMEV. As in vivo, infected astrocytes and oligodendrocytes of SHP-1-deficient mice were much more numerous and produced more virus than did those of normal littermate mice. These findings indicate that SHP-1 is a critical factor in controlling virus replication in the CNS glia and virus-induced demyelination.


Assuntos
Infecções por Cardiovirus/etiologia , Infecções do Sistema Nervoso Central/etiologia , Doenças Desmielinizantes/etiologia , Proteínas Tirosina Fosfatases/metabolismo , Theilovirus/patogenicidade , Animais , Astrócitos/enzimologia , Astrócitos/virologia , Encéfalo/patologia , Encéfalo/virologia , Infecções por Cardiovirus/enzimologia , Infecções por Cardiovirus/patologia , Infecções por Cardiovirus/virologia , Infecções do Sistema Nervoso Central/enzimologia , Infecções do Sistema Nervoso Central/patologia , Infecções do Sistema Nervoso Central/virologia , Doenças Desmielinizantes/enzimologia , Doenças Desmielinizantes/patologia , Doenças Desmielinizantes/virologia , Peptídeos e Proteínas de Sinalização Intracelular , Camundongos , Camundongos Endogâmicos C3H , Camundongos Endogâmicos C57BL , Camundongos Knockout , Camundongos Mutantes , Neuroglia/enzimologia , Neuroglia/virologia , Oligodendroglia/enzimologia , Oligodendroglia/virologia , Paralisia/enzimologia , Paralisia/etiologia , Paralisia/virologia , Proteína Tirosina Fosfatase não Receptora Tipo 6 , Proteínas Tirosina Fosfatases/deficiência , Proteínas Tirosina Fosfatases/genética , Medula Espinal/patologia , Medula Espinal/virologia , Theilovirus/fisiologia , Replicação Viral/fisiologia
20.
Neuroreport ; 13(2): 243-7, 2002 Feb 11.
Artigo em Inglês | MEDLINE | ID: mdl-11893918

RESUMO

Cyclin-dependent kinase 5 (Cdk5) was originally identified as a serine/threonine kinase and subsequently demonstrated to play a critical role in the development of CNS. We recently reported the novel function of Cdk5 in the neuregulin signaling pathway during the development of neuromuscular junction (NMJ). Here, we report the regulation of Cdk5 and p35 in rat skeletal muscle after nerve injury. Northern blot analysis revealed that Cdk5 and p35 transcripts were up-regulated in muscle after nerve denervation. The temporal profiles for the regulation of Cdk5 and p35 transcripts were different, suggesting that these changes in gene transcription might be regulated by different mechanism. Our finding on the ability of tetrodotoxin to induce p35 transcript in muscle suggested that electrical activity could regulate p35 expression. In addition to the induction of mRNA expression, the total Cdk5 and p35-associated kinase activity in muscle increased prominently after nerve denervation. Taken together, our findings suggest that Cdk5 and p35 may play important physiological roles in muscle regeneration following nerve injury.


Assuntos
Quinases Ciclina-Dependentes/metabolismo , Denervação , Músculo Esquelético/enzimologia , Músculo Esquelético/inervação , Paralisia/enzimologia , Nervo Isquiático , Animais , Quinase 5 Dependente de Ciclina , Quinases Ciclina-Dependentes/genética , Proteínas do Tecido Nervoso/genética , Junção Neuromuscular/enzimologia , Paralisia/induzido quimicamente , Paralisia/metabolismo , RNA Mensageiro/metabolismo , Ratos , Nervo Isquiático/efeitos dos fármacos , Tetrodotoxina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA